European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
Contenu archivé le 2024-06-25

Immunoprevention and immunotherapy of SARS infection

Final Report Summary - SARSVAC (Immunoprevention and immunotherapy of SARS infection)

The 114 days-lasting epidemic wave of the Severe acute respiratory syndrome (SARS) swept 30 countries, sickened a reported 8 422 people, left 916 patients dead in its wake, and almost completely paralysed Asia's economy. Aggressive quarantine measures and rising summer temperatures successfully terminated the first eruption of SARS and provided at least a temporal break, which allows us to consolidate what we have learned so far and plan for the future. Thus, this project was prepared in response to urgent medical and societal needs for immunopreventive (vaccination) and immunotherapeutic measures for SARS.

An integrated strategy for developing effective vaccines and for establishing effective therapeutic treatment was developed. The strategy for vaccine development followed two parallel approaches:
1. the preparation of a classical inactivated vaccine (as already done for other coronaviruses),
2. the definition of potential antigens and T/B protective epitopes th rough the study of SARS-CoV derived Virus-like particles (VLP), pivotal to the understanding of SARS-CoV morphogenesis and virion maturation.

The immunotherapeutic strategy relied on development and validation of neutralising human antibodies to SARS-Co V. Under this project, academia experts in immunology, vaccinology, and molecular biology have joined forces with industrial vaccine production experts, in order to develop preventive and therapeutic measures for SARS.